PACB - Pacific Biosciences of California, Inc.
| Previous Close | 7.34 |
| Open | 7.31 |
| Bid | 7.08 x 3100 |
| Ask | 7.39 x 1000 |
| Day's Range | 7.22 - 7.34 |
| 52 Week Range | 2.02 - 7.84 |
| Volume | 1,283,531 |
| Avg. Volume | 4,320,242 |
| Market Cap | 1.094B |
| Beta (3Y Monthly) | 1.58 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.73 |
| Earnings Date | Jan 30, 2019 - Feb 4, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.67 |
- GlobeNewswire•6 days ago
Report: Exploring Fundamental Drivers Behind SkyWest, Pacific Biosciences of California, Lennar, Regeneron Pharmaceuticals, MGM Growth Properties, and Cincinnati Bell — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Jan. 17, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Zacks•19 days ago
LMNX or PACB: Which is a Better MedTech Investment Pick?
Luminex (LMNX) scores higher than Pacific Biosciences (PACB) considering growth projections and fundamentals.
- GlobeNewswire•23 days ago
Bragar Eagel & Squire, P.C. Reminds Investors that it is Investigating the Boards of Directors of Red Hat, LSC Communications, Intersections, and Pacific Biosciences on Behalf of Stockholders and Encourages Investors to Contact the Firm
NEW YORK, Dec. 31, 2018 -- Bragar Eagel & Squire, P.C. reminds investors that it is investigating potential claims on behalf of stockholders of Red Hat, Inc., LSC.
- ACCESSWIRE•last month
INVESTOR ALERT: Monteverde & Associates PC Is Investigating The Acquisition Of Pacific Biosciences of California, Inc. Scheduled For A Shareholder Vote On January 24, 2019 – PACB
NEW YORK, NY / ACCESSWIRE / December 18, 2018 / JuanMonteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New ...
- GlobeNewswire•last month
Wolf Haldenstein Adler Freeman & Herz LLP announces that it has filed a class action complaint in the United States District Court for the Northern District of California on behalf of holders of Pacific Biosciences of California, Inc.
Wolf Haldenstein Adler Freeman & Herz LLP announces that it has filed a class action complaint in the United States District Court for the Northern District of California on behalf of holders of Pacific Biosciences of California, Inc. (“PACB”) (PACB) common stock in connection with the proposed acquisition of PACB by Illumina, Inc. (“Illumina”), announced on November 1, 2018 (the “Complaint”). The Complaint, which alleges violations of the Securities Exchange Act of 1934 against PACB and its Board of Directors (the “Board”), is captioned Wang v. Pacific Biosciences of California, Inc., et al., Case No. 3:18-cv-07450-WHA (N.D. Cal.).
- Business Wire•2 months ago
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout
Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors (the “Board”) of Pacific Biosciences of California, Inc. (“Pacific Biosciences” or the “Company”) (NASDAQ GS: PACB) related to the Company’s entry into an agreement to be acquired by Illumina, Inc. (“Illumina”) (NASDAQ GS: ILMN) in a transaction announced on November 1, 2018 (the “Proposed Transaction”). On November 1, 2018, the Board caused Pacific Biosciences to enter into an agreement and plan of merger (the “Merger Agreement”) with Illumina. Pursuant to the terms of the agreement, shareholders of Pacific Biosciences will receive $8.00 in cash for each share of Pacific Biosciences common stock.
- PR Newswire•2 months ago
SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Pacific Biosciences of California, Inc. - PACB
NEW YORK , Dec. 6, 2018 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York ...
- Zacks•2 months ago
Here's Why You Should Hold Pacific Biosciences (PACB) Now
Pacific Biosciences (PACB) is likely to gain from strong prospects in the Sequel System platform. However, the company faces cutthroat competition in the DNA sequencing market.
Market Realist•2 months agoPacific Biosciences of California Has Seen Solid Growth in 2018
Pacific Biosciences of California stock rose from $2.64 at the close of market on December 29, 2017, to $7.47 at the close of market on November 21, 2018, representing a ~183% year-to-date rise. PACB hit its 52-week high of $7.84 on November 8. On November 1, Pacific Biosciences entered into an agreement with Illumina (ILMN) wherein Illumina agreed to acquire it.
- Zacks•2 months ago
Here's Why You Should Invest in Illumina (ILMN) Stock Now
llumina (ILMN) set to take over peer in a $1.2-billion deal, which will strengthen its position in the genomics market.
- Zacks•2 months ago
Pacific Biosciences Offers Insights on Aedes aegypti Genome
Pacific Biosciences (PACB) uses its flagship Single Molecule, Real-Time technology to sequence the highest quality genome assembly for the Aedes aegypti mosquito.
- Motley Fool•2 months ago
Is This the Real Reason Illumina Acquired Pacific Biosciences?
The $1.2 billion acquisition will combine the two leading DNA sequencing technology platforms, but the battle for the future of DNA sequencing is just getting started.
- GlobeNewswire•2 months ago
PacBio’s SMRT Sequencing Provides Unprecedented Insight into Genome of Disease-causing Mosquito
Pacific Biosciences of California Inc., (PACB), the leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced that an international team of scientists have published the highest quality genome assembly to date of the Aedes aegypti mosquito genome using its Single Molecule, Real-Time (SMRT®) technology. “The high-quality genome assembly and annotation described here will enable major advances in mosquito biology and has already allowed us to carry out a number of experiments that were previously impossible,” the authors write.
- ACCESSWIRE•2 months ago
Pacific Biosciences Agrees to be Acquired in an All Cash Transaction, Analysts Review
NEW YORK, NY / ACCESSWIRE / November 12, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Pacific Biosciences of California, Inc. (PACB), a company that offers sequencing systems to help scientists resolve genetically complex problems. PacBio® sequencing systems, including consumables and software, provide a simple and fast end-to-end workflow for SMRT sequencing. On November 1, 2018, the Company announced they had signed an agreement for Illumina to acquire Pacific Biosciences in an all-cash transaction.
- Motley Fool•2 months ago
Why Alkermes' Depression Drug Stumbled, and How Illumina Plans to Profit From M&A
Here's what derailed the drug, and why Illumina is paying $1.2 billion to acquire Pacific Biosciences.
- Zacks•3 months ago
Pacific Biosciences (PACB) Reports Q3 Loss, Revenues Fall Y/Y
Pacific Biosciences (PACB) is getting acquired by Illumina (ILMN) by mid-2019.
- Zacks•3 months ago
Illumina (ILMN) Inks $1.2B Deal to Buy Pacific Biosciences
Illumina (ILMN) taking out on its peer, in the $1.2-billion acquisition deal, will further strengthen the position of the former in the genomics market.
- GlobeNewswire•3 months ago
Consolidated Research: 2018 Summary Expectations for Pacific Biosciences of California, NXP Semiconductors N.V., Consolidated Communications, Alexander & Baldwin, Willdan Group, and OneMain — Fundamental Analysis, Key Performance Indications
NEW YORK, Nov. 07, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- ACCESSWIRE•3 months ago
Big Biotech May Be After These Technologies
HENDERSON, NV / ACCESSWIRE / November 6, 2018 / Big biotech stock buybacks "have destroyed more than $12 billion in value, and generated no positive return in total, at least as a portfolio investment," ...
Market Realist•3 months agoPacific Biosciences of California Rose 67.63% on November 2
On November 2, Pacific Biosciences of California (PACB) closed at $7.56, which was 67.63% higher than its previous closing price. On November 1, Illumina (ILMN) released a press release announcing the acquisition of Pacific Biosciences of California for a total consideration of $1.2 billion. According to the press release, Illumina expects to close the deal by mid-2019. The acquisition is expected to strengthen Illumina’s position in the genome sequencing market.
- Motley Fool•3 months ago
Here's Why Illimuna Just Bought Its Biggest Competitor
Illumina surprised investors this week by announcing it's buying Pacific Biosciences. Here's how the deal could move the needle for investors.
- Associated Press•3 months ago
Apple and Kraft Heinz drop while Starbucks and Symantec rise
Stocks that moved substantially or traded heavily on Friday: Apple Inc., down $14.74 to $207.48 The company's revenue forecast disappointed Wall Street and it said it will stop reporting quarterly iPhone ...
Motley Fool•3 months agoWhy Newell Brands, VeriSign, and Pacific Biosciences of California Jumped Today
Find out which of these stocks got a buyout bid.
- Motley Fool•3 months ago
Why Pacific Biosciences of California Stock Is Skyrocketing Today
A $1.2 billion acquisition of the gene-sequencing company sends its shares into orbit.
